Amarin to Report Third Quarter 2016 Results and Host Conference Call on November 3, 2016 Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Report Third Quarter 2016 Results and Host Conference Call on November 3, 2016
Vascepa(R) (icosapent ethyl) and Eicosapentaenoic Acid (EPA) Data to Be Presented at National Lipid Association 2016 Scientific Sessions Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Vascepa(R) (icosapent ethyl) and Eicosapentaenoic Acid (EPA) Data to Be Presented at National Lipid Association 2016 Scientific Sessions
Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Key Lipid Parameters in Subgroup of Women With Very High Triglyceride Levels Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Key Lipid Parameters in Subgroup of Women With Very High Triglyceride Levels
Amarin Announces FDA New Chemical Entity Market Exclusivity Determination for Vascepa(R) (icosapent ethyl) Capsules Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces FDA New Chemical Entity Market Exclusivity Determination for Vascepa(R) (icosapent ethyl) Capsules
Amarin to Present at the Jefferies 2016 Global Healthcare Conference Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Present at the Jefferies 2016 Global Healthcare Conference
Vascepa(R) (Icosapent Ethyl) Data to Be Presented at American Diabetes Association's 76th Scientific Sessions Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Vascepa(R) (Icosapent Ethyl) Data to Be Presented at American Diabetes Association's 76th Scientific Sessions
Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Patients With Type 2 Diabetes and Persistent High Triglycerides Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Patients With Type 2 Diabetes and Persistent High Triglycerides
Amarin Appoints Michael W. Kalb Chief Financial Officer Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Appoints Michael W. Kalb Chief Financial Officer
Amarin to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
Amarin to Report Second Quarter 2016 Results and Host Conference Call at 7:30 A.M. ET on August 4, 2016 Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Report Second Quarter 2016 Results and Host Conference Call at 7:30 A.M. ET on August 4, 2016
